{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:06:15Z","timestamp":1792415175646,"version":"4.4.0"},"reference-count":88,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immuno-oncology agents, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T (CAR-T) cell therapies, are increasing in use for a growing list of oncologic indications. While harnessing the immune system against cancer cells has a potent anti-tumor effect, it can also cause widespread autoimmune toxicities that limit therapeutic potential. Neurologic toxicities have unique presentations and can progress rapidly, necessitating prompt recognition. In this article, we review the spectrum of central and peripheral neurologic immune-related adverse events (irAEs) associated with ICI therapies, emphasizing a diagnostic framework that includes consideration of the therapy regimen, timing of symptom onset, presence of non-neurologic irAEs, pre-existing neurologic disease, and syndrome specific features. In addition, we review the immune effector cell-associated neurotoxicity syndrome (ICANS) associated with CAR-T cell therapy and address diagnostic challenges specific to patients with brain metastases. As immunotherapy use grows, so too will the number of patients affected by neurotoxicity. There is an urgent need to understand pathogenic mechanisms, predictors, and optimal treatments of these toxicities, so that we can manage them without sacrificing anti-tumor efficacy.<\/jats:p>","DOI":"10.1093\/noajnl\/vdab107","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T06:24:57Z","timestamp":1638339897000},"page":"v108-v120","source":"Crossref","is-referenced-by-count":20,"title":["A review of neurotoxicities associated with immunotherapy and a framework for evaluation"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8435-2764","authenticated-orcid":false,"given":"Leeann B","family":"Burton","sequence":"first","affiliation":[{"name":"Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Eskian","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda C","family":"Guidon","sequence":"additional","affiliation":[{"name":"Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7793-654X","authenticated-orcid":false,"given":"Kerry L","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"issue":"8","key":"2021120107345891400_CIT0001","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"issue":"2","key":"2021120107345891400_CIT0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med."},{"issue":"26","key":"2021120107345891400_CIT0003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory Large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"5","key":"2021120107345891400_CIT0004","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"issue":"3","key":"2021120107345891400_CIT0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-Approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2021120107345891400_CIT0006","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s13046-019-1426-2","article-title":"Immunotherapy of brain metastases: breaking a \u201cdogma\u201d","volume":"38","author":"Di Giacomo","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"issue":"12","key":"2021120107345891400_CIT0007","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"5","key":"2021120107345891400_CIT0008","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol."},{"issue":"20","key":"2021120107345891400_CIT0009","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood."},{"key":"2021120107345891400_CIT0010","article-title":"Consensus disease definitions for neurologic immune related adverse events of immune checkpoint inhibitors","author":"Guidon","year":"2021","journal-title":"JITC"},{"key":"2021120107345891400_CIT0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer."},{"issue":"4","key":"2021120107345891400_CIT0012","doi-asserted-by":"crossref","first-page":"448","DOI":"10.21147\/j.issn.1000-9604.2020.04.03","article-title":"Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases","volume":"32","author":"Su","year":"2020","journal-title":"Chin J Cancer Res."},{"issue":"1","key":"2021120107345891400_CIT0013","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"1","key":"2021120107345891400_CIT0014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"16","key":"2021120107345891400_CIT0015","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"2021120107345891400_CIT0016","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/onco.13740","article-title":"Temporal trends and outcomes among patients admitted for immune-related adverse events: a single-center retrospective cohort study from 2011 to 2018","volume":"26","author":"Molina","year":"2021","journal-title":"Oncologist."},{"issue":"11","key":"2021120107345891400_CIT0017","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology."},{"issue":"10","key":"2021120107345891400_CIT0018","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin Transl Oncol."},{"issue":"1","key":"2021120107345891400_CIT0019","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mus.26070","article-title":"Neuromuscular complications of immune checkpoint inhibitor therapy","volume":"58","author":"Kolb","year":"2018","journal-title":"Muscle Nerve"},{"issue":"3","key":"2021120107345891400_CIT0020","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1002\/mus.27143","article-title":"Dual hereditary and immune-mediated neuromuscular diagnoses after cancer immunotherapy","volume":"63","author":"Jiwa","year":"2021","journal-title":"Muscle Nerve."},{"issue":"12","key":"2021120107345891400_CIT0021","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"2021120107345891400_CIT0022","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer."},{"issue":"2","key":"2021120107345891400_CIT0023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med."},{"key":"2021120107345891400_CIT0024","first-page":"JCO2017776385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"2021120107345891400_CIT0025","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology."},{"issue":"11","key":"2021120107345891400_CIT0026","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook","volume":"8","author":"M\u00f6hn","year":"2019","journal-title":"J Clin Med"},{"issue":"16","key":"2021120107345891400_CIT0027","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1212\/WNL.0000000000011812","article-title":"Inducing or \u201cUnmasking\u201d autoimmunity? the role of immune checkpoint therapy in propagating neurologic immune-related adverse events","volume":"96","author":"Gardin","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"2021120107345891400_CIT0028","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000967","article-title":"Longitudinally extensive myelitis associated with immune checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021120107345891400_CIT0029","doi-asserted-by":"crossref","first-page":"538695","DOI":"10.3389\/fneur.2020.538695","article-title":"Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature","volume":"11","author":"Oliveira","year":"2020","journal-title":"Front Neurol."},{"issue":"4","key":"2021120107345891400_CIT0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/08820538.2021.1890796","article-title":"Neuro-ophthalmic complications of immune-checkpoint inhibitors","volume":"36","author":"Mukharesh","year":"2021","journal-title":"Semin Ophthalmol."},{"issue":"2","key":"2021120107345891400_CIT0031","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"2021120107345891400_CIT0032","doi-asserted-by":"crossref","first-page":"20420986211004745","DOI":"10.1177\/20420986211004745","article-title":"Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review","volume":"12","author":"Thouvenin","year":"2021","journal-title":"Ther Adv Drug Saf."},{"issue":"42","key":"2021120107345891400_CIT0033","doi-asserted-by":"crossref","first-page":"73312","DOI":"10.18632\/oncotarget.20272","article-title":"Leptomeningeal disease: current diagnostic and therapeutic strategies","volume":"8","author":"Nayar","year":"2017","journal-title":"Oncotarget."},{"issue":"9","key":"2021120107345891400_CIT0034","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol."},{"issue":"9843","key":"2021120107345891400_CIT0035","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(12)60069-5","article-title":"Adult primary central nervous system vasculitis","volume":"380","author":"Salvarani","year":"2012","journal-title":"Lancet."},{"issue":"5","key":"2021120107345891400_CIT0036","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/ccr3.2122","article-title":"Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer","volume":"7","author":"Kim","year":"2019","journal-title":"Clin Case Rep."},{"issue":"8","key":"2021120107345891400_CIT0037","first-page":"1546","article-title":"How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy","volume":"9","author":"Ma","year":"2019","journal-title":"Am J Cancer Res."},{"issue":"6","key":"2021120107345891400_CIT0038","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1754-9485.2011.02319.x","article-title":"Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis","volume":"55","author":"Gunjur","year":"2011","journal-title":"J Med Imaging Radiat Oncol."},{"issue":"2","key":"2021120107345891400_CIT0039","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cncr.23562","article-title":"Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide","volume":"113","author":"Taal","year":"2008","journal-title":"Cancer."},{"issue":"13","key":"2021120107345891400_CIT0040","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol."},{"key":"2021120107345891400_CIT0041","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.intimp.2018.03.018","article-title":"Pseudoprogression and hyperprogression after checkpoint blockade","volume":"58","author":"Wang","year":"2018","journal-title":"Int Immunopharmacol."},{"issue":"4","key":"2021120107345891400_CIT0042","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archneur.57.4.553","article-title":"Cerebrospinal fluid oligoclonal IgG bands in patients with spinal arteriovenous malformation and structural central nervous system lesions","volume":"57","author":"Cohen","year":"2000","journal-title":"Arch Neurol."},{"issue":"6","key":"2021120107345891400_CIT0043","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1634\/theoncologist.2016-0366","article-title":"Case report: encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma","volume":"22","author":"Bossart","year":"2017","journal-title":"Oncologist."},{"issue":"1","key":"2021120107345891400_CIT0044","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13256-018-1786-9","article-title":"Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report","volume":"12","author":"Kopeck\u00fd","year":"2018","journal-title":"J Med Case Rep."},{"issue":"8","key":"2021120107345891400_CIT0045","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin Neurophysiol."},{"issue":"6","key":"2021120107345891400_CIT0046","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology."},{"issue":"5","key":"2021120107345891400_CIT0047","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.semarthrit.2013.10.007","article-title":"Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors","volume":"43","author":"Birnbaum","year":"2014","journal-title":"Semin Arthritis Rheum."},{"issue":"1","key":"2021120107345891400_CIT0048","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"11","key":"2021120107345891400_CIT0049","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology."},{"issue":"10","key":"2021120107345891400_CIT0050","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology."},{"key":"2021120107345891400_CIT0051","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","article-title":"Inflammatory myopathy associated with PD-1 inhibitors","volume":"100","author":"Seki","year":"2019","journal-title":"J Autoimmun."},{"key":"2021120107345891400_CIT0052","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer."},{"issue":"2","key":"2021120107345891400_CIT0053","doi-asserted-by":"crossref","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun."},{"issue":"1","key":"2021120107345891400_CIT0054","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: cardiooncology primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC Cardiooncol."},{"issue":"7","key":"2021120107345891400_CIT0055","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation."},{"issue":"4","key":"2021120107345891400_CIT0056","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds","year":"2019","journal-title":"Oncologist."},{"key":"2021120107345891400_CIT0057","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2017"},{"key":"2021120107345891400_CIT0058","article-title":"Management of immunotherapy-related toxicities, V3.2021","author":"Thompson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2021120107345891400_CIT0059","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw."},{"issue":"6","key":"2021120107345891400_CIT0060","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist."},{"issue":"1","key":"2021120107345891400_CIT0061","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer."},{"key":"2021120107345891400_CIT0062","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"8","key":"2021120107345891400_CIT0063","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"issue":"12","key":"2021120107345891400_CIT0064","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"issue":"2","key":"2021120107345891400_CIT0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2021120107345891400_CIT0066","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"2021120107345891400_CIT0067","doi-asserted-by":"crossref","first-page":"627764","DOI":"10.3389\/fimmu.2021.627764","article-title":"Biomarkers for chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia: prospects for personalized management and prognostic prediction","volume":"12","author":"Hong","year":"2021","journal-title":"Front Immunol."},{"key":"2021120107345891400_CIT0068","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","author":"Morris","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2021120107345891400_CIT0069","doi-asserted-by":"crossref","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Sci Rep."},{"issue":"1","key":"2021120107345891400_CIT0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes","volume":"23","author":"Holtzman","year":"2021","journal-title":"Neuro Oncol."},{"issue":"12","key":"2021120107345891400_CIT0071","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-Cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol."},{"key":"2021120107345891400_CIT0072","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol."},{"issue":"23","key":"2021120107345891400_CIT0073","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood."},{"key":"2021120107345891400_CIT0074","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol."},{"issue":"1","key":"2021120107345891400_CIT0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T Cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"2021120107345891400_CIT0076","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noab077","article-title":"Evaluation of mid-term (6\u201312 months) neurotoxicity in B-cell lymphoma patients treated with CAR T-cells: a prospective cohort study","author":"Maillet","year":"2021","journal-title":"Neuro Oncol"},{"issue":"11","key":"2021120107345891400_CIT0077","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2021120107345891400_CIT0078","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4049\/jimmunol.1701155","article-title":"Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy","volume":"200","author":"Srivastava","year":"2018","journal-title":"J Immunol."},{"issue":"12","key":"2021120107345891400_CIT0079","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of Chimeric Antigen Receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol Res."},{"issue":"14","key":"2021120107345891400_CIT0080","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pros.23214","article-title":"Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response","volume":"76","author":"Junghans","year":"2016","journal-title":"Prostate."},{"key":"2021120107345891400_CIT0081","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J Immunother Cancer."},{"issue":"5","key":"2021120107345891400_CIT0082","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther."},{"issue":"5","key":"2021120107345891400_CIT0083","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41417-019-0104-z","article-title":"HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases","volume":"27","author":"Katz","year":"2020","journal-title":"Cancer Gene Ther."},{"issue":"4","key":"2021120107345891400_CIT0084","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J Immunother."},{"issue":"399","key":"2021120107345891400_CIT0085","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"issue":"8","key":"2021120107345891400_CIT0086","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"issue":"18","key":"2021120107345891400_CIT0087","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2021120107345891400_CIT0088","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1078-0432.CCR-20-0245","article-title":"The changing landscape of therapeutic cancer vaccines-novel platforms and neoantigen identification","volume":"27","author":"Jou","year":"2021","journal-title":"Clin Cancer Res."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/3\/Supplement_5\/v108\/41355735\/vdab107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/3\/Supplement_5\/v108\/41355735\/vdab107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T16:09:21Z","timestamp":1673885361000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/3\/Supplement_5\/v108\/6444228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":88,"journal-issue":{"issue":"Supplement_5","published-print":{"date-parts":[[2021,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdab107","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,11,1]]}}}